Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Long-term Study to Evaluate the Maintenance of Efficacy and Safety of 1 to 3 mg/Day of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01838681 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT01838681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01838681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Long-term Study to Evaluate the Maintenance of Efficacy and Safety of 1 to 3 mg/Day of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Lead sponsor
H. Lundbeck A/S
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2013
Completion date
June 30, 2016
Enrollment
1,986 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder